Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Simonson PD, Lee AY, Wu D. Potential for Process Improvement of Clinical Flow Cytometry by Incorporating Real-Time Automated Screening of Data to Expedite Addition of Antibody Panels. Am J Clin Pathol. 2022;157(3):443-450.

Gao X, Wang Y, Ribeiro CF, Manokaran C, Chang H, Von T, et al. Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Mol Cancer Res. 2022;20(5):673-685.

Devereaux KA, Souers RJ, Merker JD, Lindeman NI, Graham RP, Hameed MR, et al. Clinical Testing for Tumor Cell-Free DNA. Arch Pathol Lab Med. 2022.

Devereaux KA, Souers RJ, Graham RP, Portier BP, Surrey LF, Yemelyanova A, et al. Neoplastic Cellularity Assessment in Molecular Testing. Arch Pathol Lab Med. 2022;146(9):1062-1071.

Alilou M, Khorrami M, Prasanna P, Bera K, Gupta A, Viswanathan VS, et al. A tumor vasculature-based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors. Sci Adv. 2022;8(47):eabq4609.

Pham K, Gottesdiener L, Simon MS, Trzebucki A, Maldarelli GA, Cisse B, et al. Corrigendum to: Meningovascular Syphilis Presenting as a Brain Mass in an Immunocompetent Male. Open Forum Infect Dis. 2022;9(1):ofab635.

Deshpande AS, Ulahannan N, Pendleton M, Dai X, Ly L, Behr JM, et al. Identifying synergistic high-order 3D chromatin conformations from genome-scale nanopore concatemer sequencing. Nat Biotechnol. 2022;40(10):1488-1499.

Magro CM, Mo JH, Telang G. Localized lymphomatoid papulosis: Unilesional lymphomatoid papulosis, regional lymphomatoid papulosis, and persistent agmination of lymphomatoid papulosis. Clin Dermatol. 2022;40(6):622-638.

Anderson KC, Cantley LC, Dalla-Favera R, Van Dang C, Diaz LA, DuBois RN, et al. The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Prev Res (Phila). 2022;15(11):705-712.

Bychkovsky BL, Li T, Sotelo J, Tayob N, Mercado J, Gomy I, et al. Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program. Clin Cancer Res. 2022;28(11):2349-2360.